Adjuvant chemotherapy for resectable pancreatic ductal adenocarcinoma: a single-center retrospective study
Background Adjuvant chemotherapy improves survival after resection of pancreatic ductal adenocarcinoma (PDAC), but the comparative outcomes of gemcitabine monotherapy (G) and gemcitabine plus S-1 (GS) in routine practice remain uncertain. This study aimed to analyze the associations of chemotherapy regimen and treatment completion with survival. Methods We retrospectively evaluated patients undergoing curative-intent resection for PDAC at Peking University First Hospital between January 2010 and April 2022. Overall survival (OS) and disease-free survival (DFS) were assessed using Kaplan–Meier analysis and multivariable Cox proportional hazards models. Sensitivity analyses included modeling chemotherapy initiation as a time-dependent exposure and comparing restricted mean survival time (RMST) between the G and GS groups over a 36-month horizon. Results The cohort included 245 patients, of whom 173 received postoperative chemotherapy; 46 received G and 90 received GS. Date-derived survival analyses included 242 evaluable patients. Median OS was 30.00 months (95% CI, 19.88–36.07) and median DFS was 15.93 months (95% CI, 12.52–24.57). For GS versus G, adjusted HRs were 1.28 (95% CI, 0.72–2.28) for OS and 1.36 (95% CI, 0.78–2.37) for DFS. Conclusions No significant differences in OS or DFS were observed between G and GS in this cohort. The exploratory associations between chemotherapy completion and survival need confirmation in studies that account for treatment timing and potential confounding.
Authors
- Jianqiao Yang (ORCID: https://orcid.org/0000-0002-3554-3991)
- Fusheng Zhang (ORCID: https://orcid.org/0000-0001-6693-8606)
- Yiran Chen
- Yinmo Yang
- Weikang Liu
- Xiaodong Tian
- Xuewei Sun
- Yongsu Ma
Institutions
- Peking University First Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3389/fonc.2026.1969731
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00